University Medical Center Freiburg

Novel MRI Reveals Brain Changes in Long-COVID Patients

Retrieved on: 
Wednesday, November 22, 2023
Interventional radiology, Health, RSNA, Brain, Research, Deficit spending, Tissue, DMI, Myalgia, Fatigue, COVID-19, History, Patient, University Medical Center Freiburg, Neuroradiology, Movement, Smell, Cognition, Newsroom, Infection, Atrophy, Risk, Syndrome, Education, MRI, Female, Society, Hospital, Taste, Radiology, Diagnosis, Radiation, COVID, Smoking, Pharmaceutical industry, Medical imaging

Diffusion microstructure imaging (DMI), a novel MRI technique, is a promising approach to fill this gap.

Key Points: 
  • Diffusion microstructure imaging (DMI), a novel MRI technique, is a promising approach to fill this gap.
  • It can detect even very small changes in the brain, not detectable with conventional MRI.
  • The findings also revealed a correlation between microstructural changes and symptom-specific brain networks associated with impaired cognition, sense of smell and fatigue.
  • The researchers hope to reexamine the patients in the future, recording both clinical symptoms and changes to the brain's microstructure.

Universal Medical Announces 2023 Interim Results

Retrieved on: 
Thursday, August 24, 2023
Pressure, Maintenance, China Central Television, Bed, Continuity, Nephrology, Kidney, Hospital, University Medical Center Freiburg, Central Television, Canadian Rural Revitalization Foundation, Competition (economics), Howard Hughes Medical Institute, Internet, ROA, Acquisition, Patient, Profit margin, Specialty, Growth, United States Secretary of Labor, Diagnosis, Healthcare industry, R, ESG, ROE, Internal, Pharmaceutical industry, Nursing, Bank, PRC

HONG KONG, Aug 24, 2023 - (ACN Newswire) - Genertec Universal Medical Group Company Limited (the "Universal Medical" or "Company"; Stock Coke: 2666.HK) is pleased to announce the interim results for the six months ended 30 June 2023.

Key Points: 
  • HONG KONG, Aug 24, 2023 - (ACN Newswire) - Genertec Universal Medical Group Company Limited (the "Universal Medical" or "Company"; Stock Coke: 2666.HK) is pleased to announce the interim results for the six months ended 30 June 2023.
  • As at 30 June 2023, the number of consolidated medical institutions increased to 55 (including four Grade III Class A hospitals and 26 Grade II hospitals), with a capacity of 13,893 beds in total.
  • The performance contribution of this business segment mainly comes from providing hospital clients with life cycle management of medical equipment, medical devises sales and internet-based healthcare services.
  • In August 2023, the company acquired 85% equity interests of Casstar Medical Technology Wuxi Co., Ltd. ("Casstar") at the consideration of RMB467.5 million.

Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)

Retrieved on: 
Monday, April 24, 2023
Health, Diabetes, Clinical Trials, Research, Science, Biotechnology, University, FRCPE, Doctor of Philosophy, Ethics committee, MD, Patient, University Medical Center Freiburg, Cardiovascular Diabetology, Entrepreneurship, Bogenhausen, ECWA Evangel Hospital, T2D, Disease, Pharmaceutical industry

Fractyl Health, a commercial stage organ-editing metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D), today announces the initiation of its Revita® Global Registry Program in Germany.

Key Points: 
  • Fractyl Health, a commercial stage organ-editing metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D), today announces the initiation of its Revita® Global Registry Program in Germany.
  • On April 20, the Ethics Committee of the University of Freiburg (Germany) granted a clearance for the initiation of a registry study of the Revita System in German hospitals.
  • Patients who participate in the registry will be those with inadequately controlled type 2 diabetes (T2D) despite guideline-directed medical therapy and are interested in undergoing the Revita procedure.
  • “There is a huge, global unmet need for people with inadequately controlled T2D,” said Harith Rajagopalan, MD, PhD, Co-Founder and CEO of Fractyl Health.

Repairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1/2 Trial in Advanced Heart Failure

Retrieved on: 
Tuesday, April 4, 2023
Heart, NYHA, EHM, Clinic, Heart failure, German Center for Pediatric and Adolescent Rheumatology, University Medical Center, University Medical Center Freiburg, Clinical trial, Philippine Heart Center, Toxicology, Research, Facial muscles, Trial of the century, Patient, UMG, Observation, Entrepreneurship, Principal, B cell, Berlin, Safety, Pharmaceutical industry, Medical device, Pharmacology

The clinical trial is evaluating the safety and efficacy of iPSC1 -derived engineered human myocardium (EHM) as Biological Ventricular Assist Tissue (BioVAT) in Advanced Heart Failure (NCT04396899).

Key Points: 
  • The clinical trial is evaluating the safety and efficacy of iPSC1 -derived engineered human myocardium (EHM) as Biological Ventricular Assist Tissue (BioVAT) in Advanced Heart Failure (NCT04396899).
  • Strongly encouraged by the emerging data from the BioVAT-HF study, Repairon will continue the commercial development of the EHM technology with the aim to establish it as the therapeutic option of choice for patients with advanced heart failure."
  • "Advanced heart failure treatment requires new reparative therapies; with BioVAT-HF remuscularization of the failing heart is becoming a clinical possibility," said Professor Stefan Anker Charité Berlin.
  • The open-label, non-randomized, multi-center trial is investigating the hypothesis that cardiomyocyte implantation as BioVAT results in sustainable remuscularization and biological enhancement of myocardial performance in patients with advanced heart failure.

EQS-News: PRECISIS GmbH: EASEE – ­­­World's first minimally invasive brain pacemaker for the treatment of epilepsy receives CE-certification and is available immediately

Retrieved on: 
Friday, September 23, 2022
Cortex, Adult, MDR, National Association of Epilepsy Centers, Safety, Movement, Seizure, Department, Medical device regulation, Brain, FDA, TDCS, MDD, Thalamus, University Medical Center Freiburg, Clinical study design, Electrode, Medical Devices Directive, The New England Journal of Medicine, Certification, Patient, Epilepsy, Environment, FCS, CE, Quality of life, CTO, Psychology, Neuro, Scalp, Food, Medical device, Disease, Trial of the century, Freedom, Medicine, DEPT, Pharmaceutical industry, Wood drying, MD

Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.

Key Points: 
  • Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.
  • These drug-refractory patients wait an average of 22 years before they are offered further technical or surgical treatment options.
  • With this new, risk-minimized EASEE method, the treatment spectrum is expanded in the early phases of the disease."
  • EASEE is an acronym for Epicranial Application of Stimulation Electrodes for Epilepsy.

Universal Medical (2666.HK) Announces 2022 Interim Results

Retrieved on: 
Wednesday, August 31, 2022
ROE, Safety, Bed, Program, Vaccination, Government, Insurance, City, University Medical Center Freiburg, Humanities, Health, Hospital, The Company, Company, ROA, Group, The Group, COVID-19, Industry, Efficiency, Income, Pharmaceutical industry, Health insurance

- Pursuing Progress in Revenue, Increased by 14.1%

Key Points: 
  • - Pursuing Progress in Revenue, Increased by 14.1%
    HONG KONG, Aug 31, 2022 - (ACN Newswire) - The board of directors of Genertec Universal Medical Group Co Ltd (the "Company" or "Universal Medical"; Stock code: 2666.HK) is pleased to announce the interim results of the Company and its subsidiaries (together, the "Group") for the six months ended 30 June 2022.
  • Genertec Universal Medical Group Co., Ltd. ("Universal Medical"; 2666.HK) is a publicly listed state-owned enterprise committed to China's healthcare industry.
  • Universal Medical focuses on the fast-developing healthcare industry in China, with medical services as the core and financial business as the foundation.
  • This press release is released by PEANUT MEDIA LIMITED on behalf of Genertec Universal Medical Group Company Limited.

Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples

Retrieved on: 
Thursday, July 14, 2022
ITM, LinkedIn, Safety, Byte Beautiful: Eight Science Fiction Stories, Wuhan Institute of Virology, Twitter, PCR, Instagram, DNA sequencing, View, Institute, Multimedia, Research, University Medical Center Freiburg, Monkeypox virus, Monkeypox, Transport, Collection, NGS, Solution, COVID-19, Infection, Vaccine, Facebook, Virology

This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.

Key Points: 
  • This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.
  • The DNA/RNA Shield product line includes sample collection, preservation, and transportation devices for specimens used in research and infectious disease testing workflows.
  • DNA/RNA Shield has enabled researchers to conduct infectious disease research and testing over the past decade, including throughout the COVID-19 pandemic.
  • Zymo Research offers several devices that can be filled with DNA/RNA Shield, including the popular SafeCollect Swab Collection Kit.

Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples

Retrieved on: 
Thursday, July 14, 2022
ITM, LinkedIn, Safety, Byte Beautiful: Eight Science Fiction Stories, Wuhan Institute of Virology, Twitter, PCR, Instagram, DNA sequencing, Institute, Research, University Medical Center Freiburg, Monkeypox virus, Monkeypox, Transport, Collection, NGS, Solution, COVID-19, Infection, Vaccine, Facebook, Virology

This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.

Key Points: 
  • This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.
  • The DNA/RNA Shield product line includes sample collection, preservation, and transportation devices for specimens used in research and infectious disease testing workflows.
  • DNA/RNA Shield has enabled researchers to conduct infectious disease research and testing over the past decade, including throughout the COVID-19 pandemic.
  • Zymo Research offers several devices that can be filled with DNA/RNA Shield, including the popular SafeCollect Swab Collection Kit.

Universal Medical Announces 2021 Annual Results: Business with Steady Promotion, Net Profit of Hospital Group Increased by 39.5%

Retrieved on: 
Tuesday, March 29, 2022
Company, Nephrology, Income, ROA, Health, ROE, Expansion, Program, Hospital, Bed, Profit, Humanities, Universal health care, Safety, Industry, University Medical Center Freiburg, Maintenance, Advantage, Industrial, Patient, Animal, Health insurance, Gasoline, Risk management, Group, Efficiency

-- For the year ended 31 December 2021, the return on equity was 15.37%, and the return on total assets was 3.09%.

Key Points: 
  • -- For the year ended 31 December 2021, the return on equity was 15.37%, and the return on total assets was 3.09%.
  • Genertec Universal Medical Group Co., Ltd ("Universal Medical") is a publicly listed state-owned enterprise committed to China's healthcare industry.
  • Universal Medical focuses on the fast-developing healthcare industry in China, with medical services as the core and financial business as the foundation.
  • This press release is released by PEANUT MEDIA LIMITED on behalf of Genertec Universal Medical Group Company Limited.

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

Retrieved on: 
Wednesday, October 20, 2021
Short bowel syndrome, GI, IND, Acquisition, Liver, Paneth cell, Metabolism, SBS, Form, Inborn errors of metabolism, COVID-19, Nutrient, Lists of diseases, Investigational New Drug, U.S. Securities and Exchange Commission, Patient, Phrase, Manufacturing execution system, Security (finance), Skin, Drug development, GVHD, Failure, Disease, Community of Metros, III, Interim, FDA, Nasdaq, Paneth, PS, GLOBE, Congenital disorders of amino acid metabolism, Survival, MMA, Graft-versus-host disease, Forward-looking statement, Compliance, University Medical Center Freiburg, Cancer, Food, HSCT, COA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Propionic acidemia, Mortality, Safety, Pharmaceutical industry

BASEL, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial called STARGAZE (Study of Apraglutide in Graft-Versus-Host Disease), for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD).

Key Points: 
  • We have demonstrated promising preclinical results with apraglutide as a novel approach to treating acute graft-versus-host disease, showing a significant reduction in mortality after treatment with apraglutide in mouse models.
  • STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD.
  • Apraglutide is also being evaluated in steroid-refractory acute graft-versus-host disease (aGVHD) and has demonstrated improvements in survival in pre-clinical aGVHD models.
  • It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).